Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The
...
vaccine was developed during the West Africa Ebola epidemic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
April 19,2021
MEDBOX Issue Brief no.12
The Lancet, Early Online Publication, 11 July 2014
doi:10.1016/S0140-6736(14)60934-X
*Free registration is required to view this article
This presentation presents the issues we confront in deciding how to communicate to the public that COVID-19 vaccine recommendations reflect the state of scientific knowledge.
This article is part two in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. This article focuses on the ingredients in a
...
vaccine and the three clinical trial phases. Part three outlines the next part of the vaccine journey: the steps from completing the clinical trial phases through to distribution
Available in English, French, Spanish, Arabic, Chinese and Russian
more
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this
...
vaccine, epidemics due to Neisseria meningitidis serogroup A (NmA) are disappearing, but other serogroups (e.g. NmW, NmX and NmC) still cause epidemics, albeit at a lower frequency and of a smaller size. Due to these changes, WHO organized the review of the evidence to provide recommendations for epidemic control, related to operational thresholds for investigation and response to outbreaks, the use of rapid diagnostic tests, antibiotic regimens in epidemics, and prophylaxis for household contacts of cases
more
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
Learn what scientists look for in the different phases of a clinical trial for a vaccine. What does it mean when a vaccine
...
trial is halted due to an adverse event? WHO’s Dr Kate O’Brien explains in Science in 5 this week
more
Clinical Medicine
JCI Insight. 2017;2(7):e91963.
Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
Interim Guidance, 12 July 2021; This tool was developed to assess present and surge capacities for the treatment of COVID-19 in health facilities. It allows health facilities to assess the availability and status of stockout of critical COVID-19 medicines, equipment and supplies on site and to ident
...
ify areas that need further attention to enable the facility to respond effectively to the pandemic. The tool encompasses key components that are essential to managing COVID-19 in a hospital setting, including:
health workforce (numbers, absences, COVID-19 infections, staff vaccinated for COVID-19 health workforce management, training and support);
medicines and medical supplies for management of COVID-19;
IPC capacities (protocols, safety measures, guidelines) and the availability of personal protective equipment (PPE) for staff;
diagnostic testing, imaging and patient monitoring devices and supplies
medical equipment for management of COVID-19, including O2 administration;
COVID-19 vaccine readiness ;
beds and space capacity.
more
14 July 2021 This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained se
...
ries.
COVID-19 vaccines have proven to be safe, effective and life-saving. Like all vaccines, they do not fully protect everyone who is vaccinated, and we do not yet know how well they can prevent people from transmitting the virus to others. So as well as getting vaccinated, we must also continue with other measures to fight the pandemic.
Available in English, French, Spanish, Arabic, Chinese and Russian
more
17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so
...
cial disruption and economic consequences of COVID-19, curtail the emergence of new SARS-CoV-2 variants of concern (VOCs) and ultimately control the pandemic.
more